Palvella Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Palvella Therapeutics, Inc. (PVLA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$41.78 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-31
- Palvella Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$41.78M.
- Palvella Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$17.43M.
- Palvella Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$9.82M.
- Palvella Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$11.77M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$41.78M 10-K · filed 2026-03-31 | |
| 2024-12-31 | -$17.43M 10-K · filed 2026-03-31 | |
| 2023-12-31 | -$9.82M 10-K · filed 2024-03-29 | |
| 2022-12-31 | -$11.77M 10-K · filed 2024-03-29 | |
| 2021-12-31 | -$11.31M 10-K · filed 2023-03-31 | |
| 2020-12-31 | -$12.13M 10-K · filed 2022-03-02 | |
| 2019-12-31 | -$12.06M 10-K · filed 2021-03-31 | |
| 2018-12-31 | -$10.63M 10-K · filed 2020-03-13 | |
| 2017-12-31 | -$13.84M 10-K · filed 2019-03-18 | |
| 2016-12-31 | -$8.72M 10-K · filed 2018-03-15 | -$8.72M 10-K · filed 2017-03-30 |
| 2015-12-31 | -$7.56M 10-K · filed 2017-03-30 | |
| 2014-12-31 | -$1.24M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |